戻る Agenda
[Session 6] Strategies to Assess, Prevent and Mitigate Cardiotoxicity
Session Chair(s)
Yuji Kumagai, MD, PhD
Professor, Kitasato Clinical Research Center
Kitasato University Hospital, Japan
Boaz Mendzelevski, MD
Consultant Cardiologist
Cardiac Safety Consultants Ltd., United Kingdom
Speaker(s)
Cardiovascular Safety Assessments of Oncology Drugs in Clinical Development
Boaz Mendzelevski, MD
Cardiac Safety Consultants Ltd., United Kingdom
Consultant Cardiologist
Important Adverse Effects of Molecular-Targeting Drugs in Aspects of Cardio-Oncology
Manabu Minaimi, MD, PhD
Kyoto University Hospital, Japan
Institute for Advancement of Clinical and Translational Science (iACT)
TKI Induced Cardiotoxicity and Drug-Induced Thrombosis
Wataru Shioyama, MD, PhD
Osaka International Cancer Institute, Japan
Deputy Manager, Department of Cardiovascular Medicine, Onco-Cardiology Unit
Oncology Drug-Induced Cardiotoxicity: Strategies to Assess, Prevent and Mitigate Cardiotoxicity Pre- and Post-Approval
Krishna Prasad, DrMed, MD, MRCP, FRCP
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Deputy Director, Innovative Medicines, HQA/Licensing
Cardio-Oncology from the Regulator’s Perspective
Hitoshi Kanno, MD, PhD
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Reviewer, Office of New Drug V